Home » Dreams for Iclusig as Front-Line Treatment Dashed for Now
Dreams for Iclusig as Front-Line Treatment Dashed for Now
October 24, 2013
Ariad Pharmaceuticals cited safety concerns in pulling the plug on a key Phase III trial for its drug Iclusig, which it had hoped would support front-line approval of the drug to treat blood cancer. The drug initially received unusually swift agency review and approval — a decision a top agency advisor stood behind as necessary to address certain patients’ unmet needs.